Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer. Dr. Farwell brings expertise in clinical development and medical affairs in neuromuscular diseases and oligonucleotide therapies.
Dr. Farwell joins Dyne from Biogen, Inc., where he was vice president, global head of neuromuscular diseases, medical affairs. During his 10 years at Biogen, Dr. Farwell led the development and life cycle management of SPINRAZA® (nusinersen), an oligonucleotide and the first therapy approved for the treatment of spinal muscular atrophy. He also led the late-stage development of tofersen, an investigational oligonucleotide therapy for amyotrophic lateral sclerosis, oversaw clinical and biomarker development for Biogen’s neuromuscular disease portfolio, and began his tenure at the company leading pharmacovigilance for multiple product candidates.
Previously, Dr. Farwell was an Assistant Professor in Medicine at Harvard Medical School and a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System. He received his M.D. from the University of Missouri School of Medicine and an MPH in clinical effectiveness from Harvard University School of Public Health…
Recursion, a biotechnology company scaling more like a technology company, today announced the appointment of Louisa Daniels, J.D., MBA as its Chief Legal Officer and General Counsel. In her new role, Daniels will oversee Recursion’s legal and compliance functions and augment Recursion’s industry-leading executive team.
With more than 20 years in senior roles in the biopharma industry, Daniels joins Recursion from Pfizer Inc., where she served as Vice President & Assistant General Counsel. In that position, Daniels was head of the clinical development legal team and had a leading role in legal support for Pfizer’s COVID-19 vaccine program, Operation Light Speed.
Daniels previously served as Vice President & Assistant General Counsel at Pfizer from April 2008 to January 2021, where she also served as Chief Counsel of Global Product Development from May 2016 to January 2021, as Chief Counsel of Global Commercial Operations, Strategy & Portfolio Management from 2013 to 2016 and as Lead Counsel of PharmaTherapeutics R&D from 2008 to 2013. Ms. Daniels obtained her J.D. from the University of California, BerkeleySchool of Law and her M.B.A from the Paul Merage School of Business at University of California, Irvine.
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Tim Trost as Chief Financial Officer (CFO). Mr. Trost is an accomplished life sciences executive with extensive leadership experience in financial and accounting operations and strategy.
Trost joins Werewolf from Asklepios BioPharmaceutical, Inc. (AskBio), where he served as CFO until the company’s acquisition by Bayer AG in October 2020. Prior to AskBio, Mr. Trost was Senior Vice President and CFO of Chimerix, Inc., a biopharmaceutical company focused on developing treatments in oncology and biodefense, where he helped lead the company through a variety of private and public financings. Prior to Chimerix, Mr. Trost was instrumental in venture financing and collaborations as the Vice President and CFO at Argos Therapeutics, Inc., a venture capital-backed immunotherapy company, and Senior Vice President and CFO at InteCardia, Inc., a venture-backed cardiac imaging company that was acquired by Syncor International Corporation.
ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics, today announced the appointment of Brian Goldman, Ph.D., as SVP and Chief Computation Officer.
Dr. Goldman brings almost thirty years of experience in algorithms and software for molecular modeling, cheminformatics, medicinal chemistry, and image analysis. He spent the past 20 years at Vertex, where he led the methods group in the Modeling and Informatics department and focused on applying ML methods to impact drug discovery programs.
Dr. Goldman has deep chemistry roots, having earned his Ph.D. in Chemistry from the University of California at Santa Cruz where he studied differential geometry as applied to molecular surfaces and molecular similarity calculations. Prior to joining Vertex, he worked at CombiChem, a computational drug discovery firm.
Cambridge, MA based Elicio Therapeutics, a longstanding client of Occam Global’s, has strengthened its leadership team with the appointment of Annette Matthies, PhD, as Chief Business Officer. Elicio Therapeutics is advancing its ground-breaking Amphiphile technology across immunotherapy and vaccine platforms to develop therapies for cancer and infectious disease.
Annette, trained as an immunologist and broadly experienced across therapeutic areas including oncology, will spearhead Elicio’s business and corporate development initiatives with a particularly strong focus on partnership opportunities in 2021. Most recently, Annette served as VP of Corporate Development at eFFECTOR Therapeutics. Prior to that, she was an integral member of the corporate development teams of Receptos, acquired by Celgene for $7.2B, and Facet Biotech, acquired by Abbott Laboratories for $450M.
Previously, Occam had placed Christopher Haqq, MD/PhD as EVP, Head of R&D and Chief Medical Officer. More recently, Occam recruited Daphne Karydas, CFO of Syndax Pharmaceuticals, to join Elicio’s Board of Directors.
"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."Find out more Read the Case Study
"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."Find out more
"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."Find out more
"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."Find out more
“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”Find out more
Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.
Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.
The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.
Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.
Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.
Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.View all news